REFERENCES
1. Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis. 2021;17:365-70.
2. Wu XN, Xue F, Zhang N, et al. Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019. BMC Public Health. 2024;24:363.
3. Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20:5442-60.
4. Premkumar M, Anand AC. Overview of complications in cirrhosis. J Clin Exp Hepatol. 2022;12:1150-74.
5. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604.
6. Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, et al. Diagnosis and treatment of hepatocellular carcinoma: an update. World J Hepatol. 2015;7:362-76.
7. Ma Y, Wang J, Xiao W, Fan X. A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions. Front Med. 2024;11:1410668.
8. Onyirioha K, Mittal S, G Singal A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol. 2020;7:HEP25.
9. Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol. 2012;39:434-9.
10. Attia AM, Rezaee-Zavareh MS, Hwang SY, et al. Novel biomarkers for early detection of hepatocellular carcinoma. Diagnostics. 2024;14:2278.
11. Hasa E, Hartmann P, Schnabl B. Liver cirrhosis and immune dysfunction. Int Immunol. 2022;34:455-66.
12. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18:121-6.
14. Cheng QN, Yang X, Wu JF, Ai WB, Ni YR. Interaction of nonparenchymal hepatocytes in the process of hepatic fibrosis (Review). Mol Med Rep. 2021;23:364.
15. Liu SY, Tsai IT, Hsu YC. Alcohol-related liver disease: basic mechanisms and clinical perspectives. Int J Mol Sci. 2021;22:5170.
16. Lakner AM, Steuerwald NM, Walling TL, et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology. 2012;56:300-10.
17. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014;20:7312-24.
18. Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol. 2022;19:112-34.
19. Kronsten VT, Shawcross DL. Clinical implications of inflammation in patients with cirrhosis. Am J Gastroenterol. 2025;120:65-74.
20. Rodríguez-Negrete EV, Gálvez-Martínez M, Sánchez-Reyes K, et al. Liver cirrhosis: the immunocompromised state. J Clin Med. 2024;13:5582.
21. Tuchendler E, Tuchendler PK, Madej G. Immunodeficiency caused by cirrhosis. Clin Exp Hepatol. 2018;4:158-64.
22. Zhang J, Zao X, Zhang J, et al. Is it possible to intervene early cirrhosis by targeting toll-like receptors to rebalance the intestinal microbiome? Int Immunopharmacol. 2023;115:109627.
23. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-50.
24. Refolo MG, Messa C, Guerra V, Carr BI, D’Alessandro R. Inflammatory mechanisms of HCC development. Cancers. 2020;12:641.
25. Longo M, Paolini E, Meroni M, Dongiovanni P. Remodeling of mitochondrial plasticity: the key switch from NAFLD/NASH to HCC. Int J Mol Sci. 2021;22:4173.
26. Galasso L, Cerrito L, Maccauro V, et al. Inflammatory response in the pathogenesis and treatment of hepatocellular carcinoma: a double-edged weapon. Int J Mol Sci. 2024;25:7191.
27. Zhou Y, Cui G, Xu H, et al. Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis. Cell Death Dis. 2023;14:476.
28. Tornesello ML, Cerasuolo A, Starita N, et al. Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations. Front Cell Dev Biol. 2023;11:1286683.
29. Fu S, Debes JD, Boonstra A. DNA methylation markers in the detection of hepatocellular carcinoma. Eur J Cancer. 2023;191:112960.
30. Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol. 2022;13:868695.
31. Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches. Cancers. 2015;7:2397-414.
32. Yang Y, Chen D, Zhao B, et al. The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis. Cancer Med. 2023;12:9282-92.
33. Walker LS. Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun. 2013;45:49-57.
34. Darmadi D, Lindarto D, Siregar J, et al. Association between serum cytotoxic T lymphocyte antigen (CTLA)-4 level and disease progression in patients with chronic hepatitis B. Med Arch. 2023;77:142-5.
35. Sauer N, Janicka N, Szlasa W, et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol Immunother. 2023;72:3405-25.
36. Ganjalikhani Hakemi M, Jafarinia M, Azizi M, Rezaeepoor M, Isayev O, Bazhin AV. The role of TIM-3 in hepatocellular carcinoma: a promising target for immunotherapy? Front Oncol. 2020;10:601661.
37. Guo M, Yuan F, Qi F, et al. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med. 2020;18:306.
38. Guo Y, Yang X, Xia WL, et al. Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma. BMC Cancer. 2024;24:1120.
39. Ma C, Zhang Q, Greten TF. MDSCs in liver cancer: a critical tumor-promoting player and a potential therapeutic target. Cell Immunol. 2021;361:104295.
40. Eleftheriadis T, Pissas G, Antoniadi G, Liakopoulos V, Stefanidis I. Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells. Immunology. 2015;146:292-300.
41. Asghar K, Rana IA, Abubakar M, et al. High indoleamine 2,3-dioxygenase expression along with low bridging integrator-1 expression in hepatocellular carcinoma patients. Asian Pac J Cancer Prev. 2023;24:1591-600.
42. Nenu I, Toadere TM, Topor I, et al. Interleukin-6 in hepatocellular carcinoma: a dualistic point of view. Biomedicines. 2023;11:2623.
43. Tan W, Luo X, Li W, et al. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2019;40:446-56.
44. Jin X, Zhang S, Wang N, et al. High expression of TGF-β1 contributes to hepatocellular carcinoma prognosis via regulating tumor immunity. Front Oncol. 2022;12:861601.
45. Lee HA, Goh HG, Lee YS, et al. Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. BMC Gastroenterol. 2021;21:258.
46. Li N, Zhu Q, Yang C, et al. Elevated serum soluble CD14 levels in chronic HBV infection are significantly associated with HBV-related hepatocellular carcinoma. Tumour Biol. 2016;37:6607-17.
47. Kawanaka M, Nishino K, Kawada M, et al. Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis. BMC Gastroenterol. 2023;23:143.
48. Haas OA. Primary immunodeficiency and cancer predisposition revisited: embedding two closely related concepts into an integrative conceptual framework. Front Immunol. 2018;9:3136.
49. Pai SY, Lurain K, Yarchoan R. How immunodeficiency can lead to malignancy. Hematology Am Soc Hematol Educ Program. 2021;2021:287-95.
50. Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023;149:8131-41.
51. Lian J, Yue Y, Yu W, Zhang Y. Immunosenescence: a key player in cancer development. J Hematol Oncol. 2020;13:151.
52. Fu Z, Xu H, Yue L, et al. Immunosenescence and cancer: opportunities and challenges. Medicine. 2023;102:e36045.
53. Li R, Li Z, Luo W, Zhu X, Luo B. Identification of immunosenescence of unconventional T cells in hepatocellular carcinoma. Comput Biol Chem. 2024;112:108148.
54. Cogliati B, Yashaswini CN, Wang S, Sia D, Friedman SL. Friend or foe? The elusive role of hepatic stellate cells in liver cancer. Nat Rev Gastroenterol Hepatol. 2023;20:647-61.
55. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer. 2013;2:367-83.
